Statement of Need
A need for this educational activity has been determined based on previous course evaluations and the AOFAS educational curriculum. The content of this course was based on current issues and topics provided by AOFAS membership and leadership. For more information on the AOFAS CME mission, visit aofas.org/education.
Accreditation
The American Orthopaedic Foot & Ankle Society (AOFAS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Disclaimer
The material presented in this continuing medical education activity has been made available by the American Orthopaedic Foot & Ankle Society (AOFAS) for educational purposes only. This material is not intended to represent the only, nor necessarily the best, methods or procedures appropriate for the medical situation discussed, but rather is intended to present an approach, view, statement, or opinion of the authors or presenters, which may be helpful or of interest to other practitioners. Methods, techniques, and procedures demonstrated and views and opinions expressed by speakers, presenters, and faculty are their own, and do not necessarily represent those of AOFAS, nor does presentation on the program represent or constitute endorsement or promotion by AOFAS. AOFAS expressly disclaims any warranties or guarantees, expressed or implied, and shall not be liable for damages of any kind in connection with the material, methods, information, techniques, opinions, or procedures expressed, presented, or demonstrated.
Disclosure of Conflict of Interest
Disclosure Statement
AOFAS mandates all instructors, planners, and other individuals in a position to control or influence the content of an educational activity to disclose all financial relationships that you have had in the past 24 months with ineligible companies. An "ineligible company" is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All identified conflicts must be mitigated, and the education content vetted by the AOFAS for fair balance, scientific objectivity, and appropriateness. All disclosures will be provided in this final program distributed at the meeting to all program participants.
FDA Statement
Some drugs or medical devices demonstrated at this meeting have not been cleared by the FDA or have been cleared by the FDA for specific purposes only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical devices he or she wishes to use in clinical practice. AOFAS policy provides that "off label" uses of a drug or medical device may be described in its CME activities so long as the "off label" use of the drug or medical device is also specifically disclosed (i.e., it must be disclosed that the FDA has not cleared the drug or device for the described purpose). Any drug or medical device is being used "off label" if the described use is not set forth on the products approval label.
Faculty/Planner Disclosure Declaration
As an Accreditation Council for Continuing Medical Education (ACCME) provider, AOFAS has the obligation to ensure the delivery of education that is balanced and free of commercial bias. To achieve this, it is the policy of the AOFAS that all CME-related Board, committee members ("planners"), faculty, and appropriate staff disclose in writing to the learners all financial relationships that you have had in the past 24 months with ineligible companies. An "ineligible company" is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In addition to faculty members, commentators from the floor are charged with verbally disclosing any interests immediately prior to speaking. All disclosures are provided in this final program distributed at the meeting to all program participants.
In accordance with AOFAS policy:
Faculty participation in this educational activity will be predicated upon timely submission and review of AOFAS disclosure. An individual who refuses to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for, the development, management, presentation, or evaluation of the CME activity. Non-compliance will result in a faculty member being stricken from the program.
An indication of the participant's disclosure appears after his or her name as well as the commercial company or institution that provided the support. AOFAS does not view the existence of these disclosed interests or commitments as necessarily implying bias or decreasing the value of the author's participation in this activity. In addition to ensuring that presentations be free of bias, faculty members are required to ensure that all material presented and discussed will be based on best-available evidence.
DISCLOSURE OF CONFLICT OF INTEREST
Disclosure Statement
AOFAS mandates all instructors, planners, and other individuals in a position to control or influence the content of an educational activity to disclose all financial relationships that you have had in the past 24 months with ineligible companies. An “ineligible company” are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients
All identified conflicts must be mitigated, and the education content vetted by the AOFAS for fair balance, scientific objectivity, and appropriateness. All disclosures will be provided in this final program distributed at the meeting to all program participants.
FDA Statement
Some drugs or medical devices demonstrated at this meeting have not been cleared by the FDA or have been cleared by the FDA for specific purposes only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical devices he or she wishes to use in clinical practice. AOFAS policy provides that “off label” uses of a drug or medical device may be described in its CME activities so long as the “off label” use of the drug or medical device is also specifically disclosed (i.e., it must be disclosed that the FDA has not cleared the drug or device for the described purpose). Any drug or medical device is being used “off label” if the described use is not set forth on the products approval label.
Faculty/Planner Disclosure Declaration
As an Accreditation Council for Continuing Medical Education (ACCME) provider, AOFAS has the obligation to ensure the delivery of education that is balanced and free of commercial bias. To achieve this, it is the policy of the AOFAS that all CME-related Board, committee members (“planners”), faculty, and appropriate staff disclose in writing to the learners’ all financial relationships that you have had in the past 24 months with ineligible companies. An “ineligible company” are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients
In addition to faculty members, commentators from the floor are charged with verbally disclosing any interests immediately prior to speaking. All disclosures are provided in this final program distributed at the meeting to all program participants.
In accordance with AOFAS policy:
Faculty participation in this educational activity will be predicated upon timely submission and review of AOFAS disclosure. An individual who refuses to disclose all financial relationships will be disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for, the development, management, presentation, or evaluation of the CME activity. Non-compliance will result in a faculty member being stricken from the program.
An indication of the participant’s disclosure appears after his or her name as well as the ineligible company that provided the support. AOFAS does not view the existence of these disclosed interests or commitments as necessarily implying bias or decreasing the value of the author’s participation in this activity. In addition to ensuring that presentations be free of bias, faculty members are required to ensure that all material presented and discussed will be based on best available evidence.
Webinar Faculty Disclosures
James Calder, MD
Arthrex Inc.: Grant/Research Support; Paid Consultant
Arianna Gianakos, MD
Arthrex: IONA Fellowship - NYU/Arthrex
John Kennedy, MD
Arteriocyte: Paid Consultant
Arthrex Inc.: Paid Consultant
In2Bones: Paid Consultant
Gino Kerkhoffs, MD
Arthrex Inc.: Grant/Research Support; Paid Consultant
EDUCATION COMMITTEE DISCLOSURES (Planners)
Mike Aronow, MD
AAOS: Board Member/Committee Member
American Orthopaedic Foot and Ankle Society: Board Member/Committee Member
Connecticut Orthopaedic Society: Board Member/Committee Member
CreOsso, LLC: Stock or stock options
Techniques in Foot and Ankle Surgery: Editorial/Governing board - Publications
Jonathon D. Backus, MD
American Orthopaedic Foot and Ankle Society: Board Member/Committee Member
Marrow Access Technologies: Stock or Stock Options
Medline Unite: Paid Consultant, Royalties - Publisher
Callum Clark, MD
Arthrex Inc.: Speakers' Bureau
M. Truitt Cooper, MD
GLW: Stock-privately held company
In2Bones: Paid Consultant, Royalties
Smith & Nephew: Grant/Research Support
Stryker: Educational Grant
Canon Cornelius, MD
This individual reported nothing to disclose
Cesar de Cesar Netto, MD
AAOS: Board Member/Committee Member
AOFAS: Board Member/Committee Member
Artelon: Paid Consultant, Royalties
CurveBeam: Paid Consultant, Stock or stock options
Foot & Ankle International: Editorial/Governing board – Publications
Foot and Ankle Clinics: Editorial/Governing board - Publications
International WBCT Society: Board member/Committee Member
Medartis: Paid Consultant, Royalties
Paragon 28: Grant/Research Support, Paid Consultant, Royalties
Stryker: Paid Consultant
Tayco Brace: Stock-privately held company
Zimmer-Biomet: Paid Consultant, Royalties
Daniel C Farber, MD
JMEA: Stock-privately held company
Treace Medical Concepts, Inc.: Paid Consultant
Alena Frey
Staff
This individual reported nothing to disclose
Lauren Geaney, MD
American Orthopaedic Foot and Ankle Society: Board Member/Committee Member
CT Othopedic Society: Board Member/Committee Member
FAI: Editorial/Governing board – Publications
Novastep: Paid Consultant
Paragon 28: Paid consultant, Royalties
Smith & Nephew: Paid consultant
Vilex: Paid consultant
Julie Glosson
Staff
This individual reported nothing to disclose
Daniel Guss, MD
AOFAS: Board Member/Committee Member
Butterfly, Inc.: Grant/Research Support
Ossio: Paid Consultant, Stock-privately held company
Paragon 28: Fellowship Support
Amgad M. Haleem Amin, MD
Vilex, LLC: Paid Consultant
Wright/Stryker medical: Paid Consultant
Tracy Harig, MD
This individual reported nothing to disclose
Jeannie Huh, MD
This individual reported nothing to disclose
Kenneth Hunt, MD
JISAKOS: Editorial/Governing board – Publications
Panther Orthopaedics: Stock-privately held company
Paragon 28: Editorial/Governing board – Publications, Paid Consultant
Kelly K. Hynes, MD
Acumed LLC: Paid Consultant
American Orthopaedic Foot and Ankle Society: Board Member/Committee Member
Canadian Orthopaedic Foot and Ankle Society: Board Member/Committee Member
Endo Pharmaceuticals Inc: Paid Consultant
Ortho Xcel: Paid Consultant
Brandon King, MD
Heron Therapeutics: Paid Consultant
Ashlee MacDonald, MD
This individual reported nothing to disclose
Elizabeth Martin, MD
American Orthopaedic Foot and Ankle Society: Board Member/Committee Member
Max Michalski, MD
Arthrex Inc.: Grant/Research Support
Extremity Medical: Paid Consultant, Royalties, Speakers' Bureau
Mohamed Mokhtar Abd-Ella, MD
This individual reported nothing to disclose
Jennifer Moore
Staff
This individual reported nothing to disclose
Irvin Oh, MD
Innomed: Royalties
Joseph O’Neil, MD
This individual reported nothing to disclose
Christian A. Ortiz, MD
ACUMED.: Paid Consultant
AO: Board member/Committee Member
Charles Saltzman, MD
Lima: Unpaid Consultant
Nextremity Solutions: Paid Consultant
Paragon28, Inc.: Paid Consultant
Saunders/Mosby-Elsevier: Royalties – Publisher
Vilex, LLC: Paid Consultant
Zimmer Biomet: Royalties - Publisher
Glenn Shi, MD
This individual reported nothing to disclose
Monica Volesky, MD
Arthrex: Speakers' Bureau
Canadian Orthopaedic Foot and Ankle Society: Board Member/Committee Member
Wright Medical: Other Financial or Material Support
Richard Zell, MD
This individual reported nothing to disclose
Jacob Rothschild Zide, MD
Orthofix: Paid consultant
All of the relevant financial relationships listed for these individuals have been mitigated.